Found 1238 clinical trials
C2541013 MIRNA NASH
is specifically designed to evaluate the effect of a range of doses of DGAT2i alone, and DGAT2i + ACCi, on resolution of NASH or improvement in liver fibrosis, as assessed histologically (via liver
- 314 views
- 31 Aug, 2021
- 62 locations
TREATMENT OF LIVER FIBROSIS IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH)
NASH IS LIVER INFLAMMATION AND DAMAGE CAUSED BY A BUILDUP OF FAT IN THE LIVER.
- 93 views
- 03 Oct, 2019
- 1 location
A research study for patients with cystic fibrosis who might have a condition called Fibrosing Colonopathy (FC).
A research study for patients with cystic fibrosis who might have a condition called Fibrosing Colonopathy (FC).
- 574 views
- 07 Nov, 2020
- 1 location
The AURORA Study
Assessing the efficacy and safety of Cenicriviroc for the treatment of liver fibrosis in adults with non-alcoholic steatohepatitis (NASH)
- 295 views
- 23 Nov, 2020
- 1 location
NASH (Nonalcoholic Steatohepatitis)
Nonalcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. ClinSearch is enrolling volunteers with a condition called liver fibrosis from NASH
- 35 views
- 23 Nov, 2020
- 1 location
Clinical, Electrocardiographic, and Cardiac Magnetic Resonance Imaging Risk Factors Associated with Ventricular Tachyarrhythmias in Nonischemic Cardiomyopathy (MARVEN Study)
Implantable cardioverter defibrillator (ICD) for primary prevention of mortality is an approved therapy in ischemic and nonischemic cardiomyopathy patients with left ventricular ejection fraction (EF) ≤35%. However, data from clinical trials leading to this indication in nonischemic cardiomyopathy (NICM) patients were limited. The DEFINITE [1] trial (458 patients; hazard ratio …
- 350 views
- 24 Nov, 2020
- 1 location
C3711005
The study will evaluate the effect of coadministration of a range of doses of DGAT2i with 1 dose of ACCi, on hepatic steatosis and the ability of DGAT2i to mitigate ACCi-induced elevations in serum triglycerides. The study has a 2-part design with sequential conduct of Part 1 and Part 2 …
- 45 views
- 14 Sep, 2021
- 4 locations
Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that becomes worse over time. There is currently no effective treatment for it. Researchers
- 162 views
- 23 Nov, 2020
- 1 location
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)
- 227 views
- 23 Nov, 2020
- 1 location